comparator group. Subjects were excluded from the comparator cohort if they had received 152 ivacaftor at any point since 2013 or if they had incomplete microbiology data for the study 153
period. 154
Outcomes 155
The outcomes of primary interest were the annual prevalence ratios for each CF pathogen. 156
Secondary outcomes included time to P. aeruginosa infection in those previously 157 uninfected, and vice versa: time to P. aeruginosa clearance in those previously infected. 158
Primary outcome analysis and adjustment 159
Prevalence of a positive respiratory culture for P. aeruginosa, Staphylococcus aureus, 160
Aspergillus spp. and the Burkholderia cepacia complex (BCC) were calculated annually 2011-161 2016. The two years preceding ivacaftor initiation in 2013 were included to allow more 162 robust comparison of pre-ivacaftor microbiological trajectories. Annual prevalence ratios 163 were calculated using two approaches. Firstly, the unadjusted ratio between the annual 164 prevalence of each pathogen in the treatment and comparator cohorts. Secondly, a log-165 binomial regression model adjusted for known confounders identified from a review of the 166 literature, see Supplement. Visual representation of identified potential associations in a 167 direct acyclic graph was used to identify variables that were confounders, but not mediators 168 or colliders, for inclusion in the model. Results from both unadjusted and adjusted analyses 169 are presented as prevalence ratios with 95% confidence intervals. 170
Acquisition and clearance analyses 171
To assess whether changes in P. aeruginosa prevalence in the ivacaftor cohort were driven 172 predominantly by changes in clearance, acquisition or a combination of the two, we 173 classified any individual with positive respiratory cultures in each of the two years prior to 174 ivacaftor initiation in 2013 as "infected" and any subject with no positive respiratorycultures in that period as "uninfected". Acquisition was defined as any member of the 176 "uninfected" group with a subsequent positive respiratory culture. Clearance was defined as 177 any member of the "infected" group without a recorded positive respiratory culture in any 178 subsequent year. Given the precise timepoints for clearance and acquisition were known 179 only within a defined 12-month period, we treated events as interval-censored data and 180 calculated the non-parametric maximum likelihood estimate for the purposes of Kaplan-181
Meier approximation. (9) 182

Sensitivity analyses 183
To address the robustness of our primary analysis we performed a number of further 184
analyses. Quantitative sample data, i.e. number of respiratory samples per year, was only 185 available for the year 2016 and consequently could not be included in the analysis 186 throughout. To test the impact of this variable on effect estimates we performed two 187 sensitivity analyses by firstly including total sputum samples in a regression model for 2016 188 data and secondly, a restricted analysis, where all subjects providing < 3 sputum samples in 189 2016 were excluded. Given an in-vitro synergism between colistimethate and ivacaftor has 190 been reported, (8) we performed a separate second restriction analysis excluding those 191 receiving inhaled colistimethate preparations at any stage during the study period. 192
Statistical analyses 193
All analyses were performed in R (v3.3.3, R Foundation for Statistical Computing, 2018 
Results: 201
Study cohort 202
In 2013, 276 people with CF and at least one G551D mutation met the inclusion criteria for 203 the ivacaftor group and 5296 were included in the non-ivacaftor comparator group, see 204 Supplement: Figure S1 ). Baseline characteristics of both groups for the year 2012 are 205 presented in Table 1 . cohort fell from 12.0% to 4.7%, but for the same time-period there was <1% change in BCC 214 prevalence in both cohorts, see Table 2 . 215
Primary outcome 216
Prevalence ratios for a positive culture between the ivacaftor group and their matched 217 comparators were calculated and are presented in Figure 2 swabs. The association between ivacaftor use and reduced P. aeruginosa remained when 231 sputum sample count was included into the multivariable model for 2016, see Table S1 . 232
Furthermore, a restricted analysis including only "sputum producers" (those individuals with 233 ≥3 sputum samples) found results consistent with the primary analysis, see Figure S3 . 234
Combination of increased clearance and reduced acquisition contribute to improved P. 235 aeruginosa rates. 236
Next we investigated whether reduced acquisition, increased clearance or both drove the 237 changes in P. aeruginosa prevalence. In those individuals with 2 years of documented P. 
Characteristics of individuals with change in P. aeruginosa status 245
Next we tested the hypothesis that subjects with a change in P. aeruginosa infection status 246 following ivacaftor initiation may have different clinical characteristics to those who did not. 247
Those who cleared P. aeruginosa whilst receiving ivacaftor were younger (25.1 ± 8.8 years 248
vs. 29.0 ± 8.3 years, p=0.03) and had a greater sweat chloride responses 6-8 weeks post-249 ivacaftor initiation, see Table 3 . Those who acquired P. aeruginosa whilst receiving ivacaftor 250 had poorer lung function at baseline (FEV1 80.9 ± 20.4 % predicted vs. 90.1 ± 18.1 % 251 predicted, p=0.005), but no other significant differences, see Table 4 . 252
Antibiotic usage 253
We compared antibiotic treatments between each group at baseline and across the study 254 period. Rates of anti-pseudomonal antibiotic usage were similar at baseline see Table 1 . Figure S4 . Finally, in an analysis restricted only to those who 258 did not receive inhaled colistimethate during the study period, we found our primary 259 analysis was robust, suggesting the previously reported in-vitro synergism between ivacaftor 260 and colistimethate was not acting as a confounder, see Figure S5 . (8) 261 262
Discussion: 263
We used longitudinal data from the UK CF Registry to investigate changes in sputum 264 microbiology associated with ivacaftor use in people with CF aged six years and above. 265
Ivacaftor use was associated with early and sustained reductions in positive respiratory 266 cultures for P. aeruginosa such that the likelihood of a positive culture was reduced by 32% 267 after three years of treatment. This association persisted even when adjusted for the 268 reduced sampling seen in those receiving ivacaftor. These findings have implications for the 269 need for ongoing chronic suppressive antimicrobial therapy in those receiving ivacaftor. 270
Significant reductions in S. aureus were also observed, but only from the second year of 271 treatment onwards and absolute reductions in prevalence were smaller than for P. 272 aeruginosa. Early reductions in Aspergillus spp. were also observed, however the relatively 273 low frequency in the ivacaftor group means this finding must be interpreted with caution. 274
No association with BCC infection was observed although given the low prevalence of BCC 275 infection, our study is likely underpowered in this regard. 276
277
The reductions in P. aeruginosa seen here are in keeping with previous smaller studies, 278
where the odds of a positive culture were reduced in the year following ivacaftor initiation. 279 (10-12) We found reduced S. aureus following ivacaftor initiation, a finding also reported by 280 a French study of 2 years ivacaftor experience but not observed in the G551D Observational 281 (GOAL) Study, a prospective observational study in the US which reported culture results 282 after one year of ivacaftor treatment. (10, 12) Here, differences to the GOAL study may be 283 partly explained by the much larger cohort and longer follow up period in our study, 284 particularly as significant reductions in S. aureus culture positivity only occurred in the latter 285 two years of our follow-up period. (10) The GOAL study lacked a comparator group and our 286 use of the UK CF Registry allowed us to confirm changes were limited to those receiving 287 ivacaftor rather than in the wider CF population. Furthermore, GOAL was a US study and 288 comparisons between different countries and healthcare systems are challenging, 289 particularly given Bessanova et al (13) recently reported reduced S. aureus in people 290 receiving ivacaftor in the US but not in the UK, where baseline S. aureus prevalence was half 291 of that in the US. The same study found similar reductions in P. aeruginosa and Aspergillus 292 spp. as seen here but only included one year of follow up. We were able to include the three 293 years post-ivacaftor initiation, the largest follow up of microbiological outcomes in this 294 discrete patient group to date. The large dataset and longer follow up allowed us to show, 295 for the first time, that changes in P. aeruginosa sputum positivity appear to be driven both 296
by increased clearance and also reduced acquisition. 297
298
The question arises as to why ivacaftor is associated with a pronounced effect against P. 299 aeruginosa in the CF lung. Although the quinolone ring in its chemical structure may confer 300 innate antibacterial properties, in-vitro studies have demonstrated most activity against 301
Gram-positive organisms such as S. aureus rather than P. aeruginosa, although when used in 302 combination with colistimethate a synergistic effect against P. aeruginosa has been 303 reported. (5-7) We found earlier and larger reductions in P. aeruginosa, regardless of 304 colistimethate use, suggesting a direct bactericidal effect from ivacaftor is not the 305 predominant mechanism for the changes we observed. Furthermore, clearance of P. 306 aeruginosa was associated with a greater sweat chloride response to ivacaftor and any 307 antimicrobial effect seems more likely related directly to CFTR restoration. 308 309 CFTR restoration has been associated with improved mucociliary clearance, which could 310 explain some of the changes we observed. (14) However, increased elimination of bacteria 311 by this mechanism should be species agnostic and might even favour elimination of species 312 such as S. aureus that do not form biofilms as readily, we found the opposite. Alternatively, 313 restoration of CFTR function has recently been associated with increased airway surface 314 liquid pH, mirroring changes within the gut where pH normalised following ivacaftorinitiation, and this may restore activity of some pH dependent innate antimicrobial 316 peptides. (14-16) Equally, such changes to regional growth conditions could 317 disproportionately affect P. aeruginosa since it is well adapted to the CFTR-defective lung, 318
where it gains a selective advantage via a number of complex physiological changes driven 319 by mutations resulting in different genotypic and phenotypic traits. (17, 18) Whilst these 320 traits allow it to successfully establish chronic infection, rapid and dramatic restoration of 321 CFTR function could potentially render it vulnerable in an environment it is no longer 322 adapted to survive. In keeping with this, ivacaftor initiation has previously been implicated 323 in reductions of mucoid but not non-mucoid P. aeruginosa. with chronic infection by these species (22-24), and imply there may be potential to safely 331 reduce the treatment burden in some patients. Indeed, one third of individuals with chronic 332 P. aeruginosa infection prior to ivacaftor initiation were culture negative at the end of the 333 study period. We found that older people with CF were less likely to eradicate pathogens, a 334 finding supported by a smaller study by Hisert et al (25) of older adults with CF. In that 335 study, although clearance of P. aeruginosa was not observed, bacterial load was initially 336 reduced following ivacaftor initiation yet increased in the second year of treatment and the 337 authors speculated that P. aeruginosa could diversify to survive in a CFTR restoredenvironment, suggesting an on-going need for anti-pseudomonal therapies in those who 339 remain culture positive. 340
341
Addressing selection bias and confounding in observational studies of drug effects is 342 inherently challenging. We used a multivariable log-binomial regression model to adjust for 343 known confounders but there remains potential for residual confounding particularly with 344 respect to unmeasured imbalance between groups. Misclassification is an inherent risk in 345 registry based studies, and in attempt to mitigate this we only included individuals with two 346 consecutive years of a similar microbiological status in our clearance and acquisition 347
analyses. Since we excluded those under the age of 6 and those with incomplete 348 microbiological data, including those who died during the study period, our findings may not 349 be generalisable to young children and those with more severe disease. Equally, a larger 350 proportion of patients were excluded from the potential comparator group than the 351 ivacaftor group due to insufficient data (most likely due to continued ivacaftor prescription 352 being dependent on regular follow up) and thus we cannot exclude a sampling bias in that 353 cohort. Given the registry based nature of this study there is also a risk of bias from inter-354 centre variation. For example respiratory culture sampling, processing and laboratory 355 assessment may differ between centres particularly with regard low volume, or low quality 356
specimens. 357 358
There is a risk of indication bias in that ivacaftor use is dictated by genotype, where some 359 are associated with increased bacterial colonisation. (26) However, groups had similar rates 360 of class I-III mutations and, importantly, had comparable sputum microbiology in both pre-361 ivacaftor years suggesting they were on similar microbiological trajectories. With regards tomicrobiology, for most of the study period the UK CF Registry recorded only the presence or 363 absence of each pathogen in that year, hence for the most part we are unable to determine 364 if the proportion of positive samples changed over time. Quantitative data for P. aeruginosa 365 was available for 2016, which allowed us to confirm the changes we observed were 366 consistent even when adjusted for reduced sampling in the ivacaftor group. 367
368
The strengths of this study lie in the large sample size and the longest follow-up period to 369 date. The large dataset afforded us by utilising the UK CF registry allowed us to demonstrate 370 for the first time that both increased clearance and reduced acquisition contributed to 371 reductions in P. aeruginosa infection following ivacaftor initiation. 372
373
Conclusion 374
In summary, we utilised national registry data to compare changes in respiratory 375 microbiology in the years after ivacaftor initiation. We found ivacaftor was associated with 376 reductions in lung infections by important CF pathogens. 377
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